Q4 2024 · 13F-HR
Merck & Co., Inc. (MRK)holdings as filed
Filed 2025-02-14 · accession 0000895345-25-000055
$258.0M
Reported value
13
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 60770K107 | MRNA | MODERNA INC | $96.0M | 37.2% | 2,308,190 | Common | SHARED |
| 71535D106 | PSNL | PERSONALIS INC | $81.2M | 31.5% | 14,044,943 | Common | SHARED |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $31.1M | 12.0% | 772,165 | Common | SHARED |
| 29384C908 | — | ENTRADA THERAPEUTICS INC | $30.1M | 11.7% | 1,739,768 | Common | SHARED |
| 014442107 | ALEC | ALECTOR INC | $6.7M | 2.60% | 3,545,719 | Common | SHARED |
| 869367102 | — | SUTRO BIOPHARMA INC | $5.0M | 1.94% | 2,723,509 | Common | SHARED |
| 00091E109 | ABSI | ABSCI CORPORATION | $2.6M | 1.01% | 998,163 | Common | SHARED |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $1.8M | 0.69% | 93,414 | Common | SHARED |
| 98422T100 | — | XILIO THERAPEUTICS INC | $1.4M | 0.55% | 1,483,758 | Common | SHARED |
| N51517105 | 4PKB | LAVA THERAPEUTICS NV | $1.1M | 0.42% | 1,149,345 | Common | SHARED |
| 14216R101 | CARM | CARISMA THERAPEUTICS INC | $616,993 | 0.24% | 1,473,240 | Common | SHARED |
| 29970R204 | EVAXUSD | EVAXION BIOTECH A/S | $458,443 | 0.18% | 542,279 | Common | SHARED |
| 64136E102 | NEUP | NEUPHORIA THERAPEUTICS INC | $34,393 | 0.01% | 10,027 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.